Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Lags Revenue Estimates
Portfolio Pulse from
Y-mAbs Therapeutics, Inc. (YMAB) reported a Q4 loss of $0.15 per share, missing the Zacks Consensus Estimate of a $0.13 loss. This is a larger loss compared to $0.02 per share a year ago.
March 04, 2025 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Y-mAbs Therapeutics reported a larger-than-expected Q4 loss of $0.15 per share, missing the consensus estimate of $0.13 and widening from last year's $0.02 loss.
The reported loss per share was larger than expected, which is typically negative for stock prices. The widening loss compared to the previous year further adds to the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100